FDA would require drug supply chain labels to go public
In committeeH.R. 8339Latest action
Sponsor: Doris O. Matsui · Representative · CA
AIDecoded by AI · checked against the recordRead the official text
Official title: Drug Origin Transparency Act of 2026
119th Congress
Topics: Health care
Introduced:
Read the official bill on Congress.govIn plain words
The plain-language version comes first. The official text is always the reference.
HR 8339 would require drug makers to report ingredient sources to the government and display that information on drug labels.
50-second read · 4 questions answered below
What does this do?
This bill requires drug manufacturers to tell the federal government who supplies each ingredient in their drugs and how much of the drug came from each supplier. Reports could be required up to four times a year. Drug labels and package documents would also have to show the name, location, and a unique ID number for every company involved in making, packing, or distributing the drug.
Who does it affect?
Drug manufacturers, ingredient suppliers, and distributors would face new reporting and labeling requirements. Consumers and pharmacists would be able to see more detail about where drugs and their ingredients are made.
Why does it matter?
Because more sourcing information would appear on labels and in government reports, the origin of a drug and its ingredients would be more traceable. The Food and Drug Administration would be responsible for writing the rules that define exactly what must be reported and how it must appear on labels.
AI-drafted summary. Check it against the official text before you act on it.
Read the official bill on Congress.govMake the call
Where does it stand?
- IntroducedApr 16, 2026
- House committeeYou are here · Apr 16, 2026
- House vote
- Senate
- The president's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the president.
Latest action: — Referred to the House Committee on Energy and Commerce.